Advertisement
Posters CLINICAL TRIALS & OUTCOME MEASURES| Volume 21, SUPPLEMENT 2, S108, October 2022

184 Effects of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles

DOI:https://doi.org/10.1016/S1569-1993(22)00874-8
184 Effects of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles
Previous Article183 Chest computed tomography assessment to monitor cystic fibrosis structural lung disease progression in bronchiectasis during late childhood and adolescence
Next Article185 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation
      This paper is only available as a PDF. To read, Please Download here.

      Article info

      Identification

      DOI: https://doi.org/10.1016/S1569-1993(22)00874-8

      Copyright

      © 2022 European Cystic Fibrosis Society. All rights reserved. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX